| HOME >> MEDICINE >> TECHNOLOGY |
Additional details for the ASCO posters or abstract are as follows:
Mon, June 6, 8:00 AM - 12:00 PM: Hall A, poster #35H
Abstract #10631 - Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISH
F. Z. Bischoff, T. J. Pircher, T. Pham, K. Wong, S. Mikolajczyk, P. Cotter, J. A. Mayer; Biocept Inc., San Diego, CA
Clinical Relevance of cytokeratin negative circulating tumor cells
C. V. Pecot, F. Z. Bischoff, Y. G. Lin, P. Jaladurgam, W. M. Merritt, T. J. Pircher, S. Mikolajczyk, J. A. Mayer, K. Wong, T. Pham, J. N. Bottsford-Miller, R. L. Stone, J. Celestino, A. M. Nick, C. Eng, A. Sood; University of Texas M. D. Anderson Cancer Center, Houston, TX; Biocept Inc., San Diego, CA; University of Southern California, Los Angeles, CA
About Biocept, Inc.
Biocept Laboratories, headquartered in San Diego, California, is an advanced CLIA-certifed laboratory services company specializing in the capture, detection, enumeration and analysis of Circulating Tumor Cells (CTCs). Biocept's mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes innovative, proprietary technologies to deliver clinically relevant and actionable information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with important information for the treatment of their patients with cancer.
About OncoCEE™
The OncoCEE™ platform, developed by Biocept, has demonstrated that it can consistently and accurately capture extremely rare cells, like CTCs, which may be present in o
'/>"/>
| SOURCE Biocept, Inc. Copyright©2010 PR Newswire. All rights reserved |